Oxular

📍 Oxford, United Kingdom🗓 Founded 2014👥 28 employees💰 Last funded 2019
Biotechnology🌐 oxular.com
Website LinkedIn
“One treatment a year. Life changing.” Oxular is developing disruptive treatments for retinal diseases. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye. This approach provides unique and precise drug distribution to tissues specifically involved in retinal diseases. Oxular’s drug administration technology is engineered to access these critical tissues through minimally invasive delivery. This unique combination aims to substantially improve patient quality of life by increasing therapeutic effectiveness and patient safety, while reducing side-effects and minimizing the frequency of treatments. Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema, as well as rare and orphan indications, including treatments for ocular cancers.
2
Total investors
1
Early stage
1
Mid stage
0
Late stage
2014
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Netherlands
1
United Kingdom
1
Frequently asked questions
Who invested in Oxular?
Oxular has 2 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage.
When did Oxular last raise funding?
The most recent investment in Oxular recorded on gritt.io was in 2019.
When was Oxular founded?
Oxular was founded in 2014.
What industry is Oxular in?
Oxular operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Oxular based?
Oxular is headquartered in Oxford, United Kingdom.